Capstone therapeutics announces publication of second data group (elevated cholesterol) from Chrysalin(r) (TP508) study demonstrating significant benefit in a pre-clinical model of acute heart disease

April 22, 2009

By hammersmith

[Source: FoxNews/GlobeNewswire via COMTEX] – Capstone Therapeutics (Nasdaq:CAPS) today announced publication of results from the second data group of a pre-clinical study demonstrating that Chrysalin(r) (rusalatide acetate or TP508), administered following the onset of ischemia, showed a statistically significant cardioprotective benefit in an elevated-cholesterol porcine model of acute myocardial infarction (AMI or heart attack).

In a pathophysiologically relevant model of AMI with either normal (first cohort, previously published as announced on March 5, 2009) or elevated cholesterol levels (second cohort, now published), intravenous administration of Chrysalin produced a significant reduction in infarct size. Importantly, the drug was administered following ischemic insult, which reflects the anticipated clinical scenario of a heart attack.

The study results from the elevated-cholesterol group are published under the title “The Effect of Thrombin Fragment (TP508) on Myocardial Ischemia Reperfusion Injury in Hypercholesterolemic Pigs” in the Journal of Applied Physiology advance online publication with the following citation: J Appl Physiol (April 16, 2009). doi:10.1152/japplphysiol.00071.2009. The abstract and full-text manuscript are available via the following link:

For more information click here.